Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859040 · ClinicalTrials.gov registry record · Phase 2
Monthly SOM230C for Recurrent or Progressive Meningioma
A Phase 2 study of Meningioma, sponsored by Patrick Y. Wen, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 8
- Study locations
NCT00859040: Completed Phase 2 study of Meningioma, sponsored by Patrick Y. Wen, MD.
NCT00859040 is a Phase 2 study of Meningioma that has completed, run by Patrick Y. Wen, MD. The registered enrollment target is 34 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (65% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00859040, a Phase 2 study of Meningioma, has completed, sponsored by Patrick Y. Wen, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those other research studies suggests that SOM230C may help to stop the growth of meningiomas.
Primary Outcome
Progression is defined using Modified Macdonald Criteria , using a \>/= 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear clinical worsening or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Conditions Studied
Interventions
- DRUG SOM230C
Study Locations (8)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- Duke University Medical Center, Preston Robert Tisch Brain Tumor Center - Durham
- Wake Forest University Baptist Medical Center - Winston-Salem
California
- Cedars-Sinai Medical Center - Los Angeles
Illinois
- Northwestern University - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT00859040 record still lists
NCT00859040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 1 intervention - of which SOM230C is the first listed.
NCT00859040 lists 8 locations in 5 states (Massachusetts, North Carolina, California).
Frequently Asked Questions
What is clinical trial NCT00859040 about?
NCT00859040 is a clinical study titled "Monthly SOM230C for Recurrent or Progressive Meningioma". The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those oth...
What is the current status of trial NCT00859040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-03. Estimated completion is 2016-01.
What conditions does trial NCT00859040 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT00859040?
The interventions under investigation include: SOM230C (DRUG).
Who is sponsoring clinical trial NCT00859040?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00859040 being conducted?
This trial has 8 study locations across California, Illinois, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00859040's enrollment target sits among peer trials
34 13th of 21 higher than 9 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia